Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T · 1 trial · 2 indications
Determine if treatment with autologous genetically modified T cells, (MAGE A10ᶜ⁷⁹⁶T ) is safe and tolerable through assessment of DLTs, AEs, including SAEs; laboratory assessments, including chemistry, hematology, and coagulation; cardiac and pulmonary assessments, including ECG and troponin.
| Arm | Type | Description |
|---|---|---|
| Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T | BIOLOGICAL | - |
Key Inclusion Criteria: 1. Subject has histologically or cytologically confirmed diagnosis of advanced non-small cell lung cancer (stage IIIB or IV) or recurrent disease 2. Subject has received at least one line of prior therapy 3. Subjects with known epidermal growth factor receptor (EGFR) mutatio...
Top 20 of 83 competitors